Skip to main content

Table 4 Association of Overall Survival and Recurrence Free Survival with Demographics and Disease Characteristics

From: Expression of the luteinizing hormone receptor (LHR) in ovarian cancer

Factors

N

Overall Survival (Months)

Recurrence Free Survival (Months)

Median (95% CI)

p-value*

Median (95% CI)

p-value*

Overall

232

44.0 (39.7, 49.9)

 

26.3 (20.9, 38.0)

 

Age at Diagnosis

  

< 0.001

 

< 0.001

 < 60

130

52.2 (45.0, 84.9)

0.18^

38.0 (22.3, 49.9)

0.26^

 ≥60

102

36.8 (25.1, 41.8)

 

22.0 (15.3, 26.6)

 

Pathologic Stage

  

< 0.001

 

< 0.001

 I/II

68

Not reached

< 0.001^

Not reached

< 0.001^

 III/IV

140

38.0 (30.1, 41.8)

 

20.0 (16.6, 24.2)

 

Silberberg’s Grade

  

< 0.001

 

< 0.001

 1

27

Not reached

0.23^

Not reached

0.060^

 2 or 3

205

41.8 (37.9, 45.9)

 

24.2 (19.1, 29.9)

 

Persistent Disease

  

< 0.001

 

< 0.001

 No

144

69.8 (52.2, 85.7)

< 0.001^

35.8 (20.9, 51.4)

0.69^

 Yes

88

24.2 (15.3, 30.5)

 

24.2 (15.3, 30.5)

 

LHR-I

  

0.28

 

0.27

 Negative/Weak/Moderate

80

51.2 (40.7, 65.9)

 

29.9 (19.0, 46.0)

 

 Strong

152

41.9 (38.0, 45.3)

 

24.5 (19.6, 38.0)

 

LHR-P

  

0.36

 

0.53

 ≤ 50%

34

50.3 (35.4, 74.3)

 

36.0 (19.0, 50.3)

 

 >  50%

197

43.8 (39.2, 49.5)

 

24.6 (20.0, 38.0)

 
  1. *p-value based on logrank test
  2. ^ p-value based on Wald test from Cox proportional model, adjusted by all other variables with p < 0.05 in univariate analysis